Back to Trial

Oracle Runs

Oracle findings and outcome history for Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection (NCT04856085).

Runs
1
Findings
1
Latest Run
Apr 1, 2026, 7:51 PM
Resolution Evidence
Outcome
YES
Status
Resolved
Settlement Date
4/1/26 UTC
Executive Summary

Exact Phase 2 MARCH/NCT04856085 readout was publicly framed as positive by the sponsor: end-of-treatment results were labeled positive/encouraging, and the later post-treatment update said the study-defined primary endpoint was achieved. Evidence is trial-specific, not pooled.

Sources
Sponsorinvestors.vir.bio11/15/24
Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study

For MARCH Phase 2, Vir said the study showed promising HBsAg loss, safety/efficacy supported continued development, and investigators called the end-of-treatment data encouraging.

View source
Sponsorinvestors.vir.bio5/9/25
Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study

Vir reported that the study-defined primary endpoint was achieved at 24 weeks post-end of treatment in low-baseline-HBsAg participants, with no new safety concerns.

View source
All Oracle Findings

Every stored oracle finding for this trial, including pending, dismissed, rejected, superseded, and accepted items.

YESAccepted93% confidenceGPT-5.4 (OpenAI)

Will the results be positive?

Exact Phase 2 MARCH/NCT04856085 readout was publicly framed as positive by the sponsor: end-of-treatment results were labeled positive/encouraging, and the later post-treatment update said the study-defined primary endpoint was achieved. Evidence is trial-specific, not pooled.

Found Apr 1, 2026, 7:51 PMOutcome date Nov 15, 2024, 12:00 AMReviewed Apr 1, 2026, 7:56 PM
Sponsorinvestors.vir.bioNov 15, 2024, 12:00 AM
Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study
For MARCH Phase 2, Vir said the study showed promising HBsAg loss, safety/efficacy supported continued development, and investigators called the end-of-treatment data encouraging.
Sponsorinvestors.vir.bioMay 9, 2025, 12:00 AM
Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study
Vir reported that the study-defined primary endpoint was achieved at 24 weeks post-end of treatment in low-baseline-HBsAg participants, with no new safety concerns.
Outcome History

Public history of accepted oracle reviews and recorded outcome changes for this trial.

Accepted Oracle Review (Legacy)Apr 1, 2026, 7:56 PM

Will the results be positive?

PendingtoYEScurrentYES
GPT-5.4 (OpenAI)93% confidenceReviewed Apr 1, 2026, 7:56 PM

Exact Phase 2 MARCH/NCT04856085 readout was publicly framed as positive by the sponsor: end-of-treatment results were labeled positive/encouraging, and the later post-treatment update said the study-defined primary endpoint was achieved. Evidence is trial-specific, not pooled.